TRCT
GMAB icon

Tower Research Capital (TRC)’s Genmab GMAB Stock Holding History

Tower Research Capital (TRC)’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$199K Buy
7,260
+6,565
+945% +$174K ﹤0.01% 1696
2026
Q1 		$18.6K Sell
695
-109,964
-99% -$3.3M ﹤0.01% 3523
2025
Q4 		$3.41M Buy
110,659
+109,647
+10,835% +$3.42M 0.08% 212
2025
Q3 		$31K Sell
1,012
-45,641
-98% -$1.11M ﹤0.01% 2905
2025
Q2 		$964K Buy
46,653
+45,618
+4,408% +$936K 0.03% 567
2025
Q1 		$20.3K Sell
1,035
-11,482
-92% -$241K ﹤0.01% 2952
2024
Q4 		$261K Buy
12,517
+5,785
+86% +$127K 0.01% 1528
2024
Q3 		$164K Sell
6,732
-25,694
-79% -$687K ﹤0.01% 1802
2024
Q2 		$815K Buy
32,426
+28,212
+669% +$800K 0.01% 925
2024
Q1 		$126K Sell
4,214
-4,004
-49% -$118K ﹤0.01% 1709
2023
Q4 		$262K Buy
8,218
+6,504
+379% +$204K ﹤0.01% 1880
2023
Q3 		$60.5K Sell
1,714
-34,933
-95% -$1.33M ﹤0.01% 2385
2023
Q2 		$1.39M Buy
36,647
+31,398
+598% +$1.25M 0.05% 346
2023
Q1 		$198K Buy
5,249
+3,498
+200% +$134K 0.01% 1378
2022
Q4 		$74K Sell
1,751
-1,648
-48% -$67.9K ﹤0.01% 2060
2022
Q3 		$109K Sell
3,399
-9,165
-73% -$322K ﹤0.01% 2490
2022
Q2 		$409K Buy
12,564
+7,936
+171% +$257K 0.01% 1263
2022
Q1 		$167K Sell
4,628
-56
-1% -$1.92K ﹤0.01% 1855
2021
Q4 		$185K Sell
4,684
-4,561
-49% -$190K ﹤0.01% 1833
2021
Q3 		$404K Buy
9,245
+8,413
+1,011% +$378K 0.01% 1152
2021
Q2 		$34K Sell
832
-2,089
-72% -$80.6K ﹤0.01% 3348
2021
Q1 		$96K Buy
+2,921
New +$110K ﹤0.01% 2614
2020
Q4 		– Sell
-1,725
Closed -$63K – 5237
2020
Q3 		$63K Buy
+1,725
New +$62.4K ﹤0.01% 3438
2020
Q2 		– Sell
-100
Closed -$2K – 4832
2020
Q1 		$2K Buy
+100
New +$2.23K ﹤0.01% 2583
2019
Q4 		– Sell
-50
Closed -$1K – 3825
2019
Q3 		$1K Buy
+50
New +$985 ﹤0.01% 3860

Other funds holding GMAB

PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Tower Research Capital (TRC)'s GMAB Position: Q2 2026 in Review

Tower Research Capital (TRC) increased its Genmab (GMAB) stake by 945% in Q2 2026, buying an estimated $174K and bringing the position to 7,260 shares worth $199K. The position accounts for ﹤0.01% of the portfolio, ranked #1696.

Tower Research Capital (TRC) first reported a position in GMAB in Q3 2019 and has held it in 25 quarters since. The position peaked at $3.41M in Q4 2025. 291 funds tracked by Wall St. Rank hold GMAB as of Q2 2026.

  • Tower Research Capital (TRC) held 7,260 shares of Genmab worth $199K as of Q2 2026.
  • Tower Research Capital (TRC) bought 6,565 Genmab shares in Q2 2026, an estimated $174K.
  • Genmab made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #1696 holding.
  • Tower Research Capital (TRC) first reported a position in Genmab in Q3 2019 and has held it in 25 quarters since.
  • Tower Research Capital (TRC)'s Genmab position peaked at $3.41M in Q4 2025.
  • 291 funds tracked by Wall St. Rank held Genmab as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.